CM Life Sciences $21 Million SPAC Securities Settlement

If you held shares of CM Life Sciences, Inc. (CMLS) Class A common stock from July 19, 2021, to July 22, 2021, you may be eligible to claim a portion of a $21,000,000 award from a class action settlement.

CM Life Sciences Holdings, LLC has agreed to pay $21,000,000 to settle a class action lawsuit for alleged breaches of fiduciary duty, aiding and abetting thereof, and unjust enrichment.

Who Are the Class Members?

The class includes all individuals and entities who held shares of CMLS Class A common stock during the specified period, either directly or indirectly. This also encompasses heirs, successors-in-interest, successors, transferees, and assigns. To clarify:

• You must have held shares between July 19, 2021, and July 22, 2021.
• Shares could be held directly or indirectly, either of record or beneficially.
• Heirs, successors-in-interest, transferees, and assigns are included.

How Much Can Class Members Get?

The settlement fund of $21,000,000 will be distributed among class members who submit valid claims. The exact amount each class member receives depends on the number of valid claims filed and the details of each claim.

Class members will receive a pro-rata share of the "Net Settlement Fund". This fund is the settlement amount plus any interest earned, minus taxes, administration costs, and attorneys' fees.

• Recognized Claim: Calculated based on the number of shares held and the sale price of those shares.
• Nominal Damages: Additional damages calculated per share.

For example, if a class member held shares that were converted and sold at a price below $10.00, the Recognized Claim for each share would be $10.00 minus the sale price, plus Nominal Damages.

How to Claim an Award

To claim an award, class members must submit a Proof of Claim and Release form. This can be done online through the online claim form or by mailing the completed form to the Settlement Administrator.

CMLS Stockholder Settlement

Settlement Administrator

c/o Gilardi & Co. LLC

P.O. Box 301133

Los Angeles, CA 90030-1133

Ensure that all supporting documentation is included with the claim form. Documentation such as stockbroker confirmation slips or statements verifying holdings and transactions of CMLS Class A common stock, Sema4 Holdings Corp. common stock, or GeneDx Holdings Corp. common stock is required.

Claims must be submitted or postmarked by December 12, 2024.

$21 million settlement fund breakdown

The settlement fund of $21,000,000 will cover various costs and payments related to the settlement:

• Class member awards based on valid claims.
• Administrative costs for processing claims.
• Attorneys' fees and expenses, not to exceed 25% of the settlement amount.
• Service awards to the plaintiffs, not exceeding $10,000 each.

Important Dates

• Deadline to File a Claim: December 12, 2024
• Fairness Hearing: December 2, 2024

When Is the GeneDx De-SPAC Litigation Payout Date?

The court will hold a Fairness Hearing on December 2, 2024, to decide whether to approve the settlement. If approved, payments will be distributed after all claims are processed.

Why Was There a Class Action Settlement?

The lawsuit alleged that the defendants breached their fiduciary duties by impairing CMLS stockholders' rights to make informed redemption decisions during the merger with Mount Sinai Genomics, Inc. The settlement was reached to avoid the costs and risks of further litigation.